Activity of second-line chemotherapy in
✍
Jonathan E. Rosenberg; Vivian K. Weinberg; W. Kevin Kelly; Dror Michaelson; Maha
📂
Article
📅
2007
🏛
John Wiley and Sons
🌐
English
⚖ 147 KB
👁 1 views
## Abstract ## BACKGROUND. This randomized, noncomparative, multicenter, clinical trial evaluated ixabepilone or mitoxantrone/prednisone (MP) as second‐line chemotherapy for taxane‐refractory, hormone‐refractory, prostate cancer (HRPC). ## METHODS. Patients with HRPC that progressed during or wi